20 May 2025 IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announces its unaudited interim results for the six months ended 31 March 2025 (‘H1 2025’ or the ‘period’).

Financial highlights

• Revenues up 26% to £3.2 million (H1 2024: £2.5m) putting the Company in a strong position to deliver or exceed guidance
• Gross margin increased by 23% to a level of 49.6% (H1 2024: 40.2%), reflecting increased revenues and thereby accessing operational leverage
• Order book of £13.1m as at 31 March 2025 (H1 2024: £12.7m)
• EBITDA loss of £0.7m to 31 March 2025 (H1 2024: £1.3m loss)
• Strong cash position £5.0 million at 31 March 2025 (H1 2024: £2.5m). The Group raised £3.7 million of new capital (net of placing costs) in October 2024

Operational highlights

• Strengthening of operations with key hires that enhance US footprint and deepen C-Suite expertise
• Exciting technology and product roadmap progress announced in Alzheimer’s and Parkinson’s disease that increases commercial opportunities
• Diversification of projects across therapeutic areas, clinical phases, geographies and customer types
• Focussed execution on the Innovate, Lead, Scale strategy, building a foundation for growth that will become increasingly visible across the second half of 2025 and into 2026.

Post period activity

• Contract signed with a major global pharmaceuticals company to provide trial management and neuroimaging analytics for a Phase 1 Huntington’s Disease clinical trial.

Bram Goorden, CEO of IXICO, commented: “The first half of 2025 indicates that our ‘Innovate Lead Scale’ strategy has created the foundations for a return to growth driven by the diversification of revenue streams, therapeutic areas and market verticals, together with the scope extension of existing client programs. It has been a positive first six months defined by disciplined commercial execution, scientific innovation and truly differentiated technology development. My conviction has been further strengthened that the Company is going to make an accelerated impact in the thriving space of neurodegenerative disease research.”     

A recording of the results presentation will be made available on the Group’s website here: https://ixico.com/investors/company-information/investor-videos/

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

For further information please contact:

IXICO plc	info@ixico.com
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	+44 (0) 20 7220 0500
Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such Alzheimer's disease, Parkinson’s disease and Huntington's disease. The Company's purpose is to advance medicine and human health by turning biomarker data into clinically meaningful information, supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image and broader biomarker analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients as they develop novel solutions for high unmet challenges in the space of neurodegenerative diseases .

More information is available on www.IXICO.com

---